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Abstract
Purpose The efficacy of levoketoconazole in treating hypercortisolism was demonstrated in an open-label phase 3 study 
(SONICS) of adults with endogenous Cushing’s syndrome (CS) and baseline mean urinary free cortisol (mUFC) ≥  1.5× 
ULN. Clinical signs and symptoms and patient-reported outcomes from the SONICS trial were evaluated in the current 
manuscript.
Methods Patients titrated to an individualized therapeutic dose entered a 6-month maintenance phase. Secondary endpoints 
included investigator-graded clinical signs and symptoms of CS during the maintenance phase, and patient-reported quality 
of life (CushingQoL questionnaire) and depression symptoms (Beck Depression Inventory II [BDI-II]).
Results Of 94 enrolled patients, 77 entered the maintenance phase following individualized dose titration. Significant mean 
improvements from baseline were noted at end of maintenance (Month 6) for acne, hirsutism (females only), and peripheral 
edema. These improvements were observed as early as Day 1 of maintenance for hirsutism (mean baseline score, 7.8; ∆ 
− 1.9; P < 0.0001), end of Month 1 for acne (mean baseline score, 2.8; ∆ − 1.2; P = 0.0481), and Month 4 for peripheral 
edema (mean baseline score, 1.0; ∆ − 0.5; P = 0.0052). Significant mean improvements from baseline were observed by 
Month 3 of maintenance for CushingQoL (mean baseline score, 44.3; ∆ + 6.9; P = 0.0018) and at Month 6 for BDI-II (mean 
baseline score, 17.1; ∆ − 4.3; P = 0.0043) scores. No significant mean improvement was identified in a composite score of 
7 other clinical signs and symptoms.
Conclusions Treatment with levoketoconazole was associated with sustained, meaningful improvements in QoL, depression, 
and certain clinical signs and symptoms characteristic of CS.
ClinialTrials.gov identifier: NCT01838551.
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Introduction
Endogenous Cushing’s syndrome (CS) is a rare and debili-
tating endocrine disease caused by prolonged elevation in 
cortisol production [1]. CS is characterized by a variety of 
clinical signs and symptoms due to hypercortisolism and/
or associated hyperandrogenism (in females), including 
changes in physical appearance (altered fat distribution, hir-
sutism, acne, skin fragility), metabolic dysregulation (insulin 
resistance, muscle catabolism), reproductive abnormalities 
(hypogonadism, menstrual irregularities), and cardiovas-
cular complications (hypertension, atherosclerosis, venous 
thromboembolism, peripheral edema) [2, 3]. Neuropsychiat-
ric consequences, notably depression, cognitive disturbance, 
anxiety, and sleep disorders, are also common [4, 5]. As a 
result of this profound multi-system impact, CS can mark-
edly impair quality of life (QoL), sometimes even after cor-
tisol levels are apparently normalized [6].
Surgery to remove the underlying neoplasia caus-
ing excess cortisol production is typically the first-line 
treatment for CS [7, 8]. Medical therapies, which include 
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pituitary-targeted agents, adrenal steroidogenesis inhibi-
tors, and a glucocorticoid receptor antagonist, are some-
times used as a temporizing measure prior to surgery; 
when hypercortisolism persists or recurs after surgery; as 
a bridging treatment until radiotherapy becomes effective; 
or as primary medical therapy in selected cases [2, 8, 9]. 
Levoketoconazole, an orally administered ketoconazole 
stereoisomer, is a potent steroidogenesis inhibitor in devel-
opment for the treatment of endogenous CS [10]. Results 
from the phase 3 SONICS (Study of levOketocoNazole In 
Cushing’s Syndrome) demonstrated that treatment with 
levoketoconazole normalized mean urinary free cortisol 
(mUFC) after 6 months of maintenance therapy (without 
a dose increase during maintenance) in 30% of patients 
who entered the study, with higher rates of mUFC nor-
malization among those who completed the maintenance 
phase [11].
Reversal of hypercortisolism has been associated with 
improvements in clinical signs and symptoms, QoL, and 
psychological functioning in patients with CS, although 
residual effects may persist [4, 12]. In SONICS, signifi-
cant mean improvements were observed from baseline to 
Month 6 of the maintenance phase in acne, hirsutism (in 
females), and peripheral edema; QoL was significantly 
improved and depression was significantly reduced [11]. 
The current manuscript reports further analysis of the 
effects of levoketoconazole on investigator-assessed clini-
cal signs and symptoms, patient-reported outcomes, and 
associated biochemical markers in SONICS.
Materials and methods
Study design and patients
SONICS was a multinational, phase 3, single-arm, open-
label study of oral levoketoconazole in the treatment of 
endogenous CS (ClinialTrials.gov: NCT01838551). The 
study was approved by an institutional review board or 
independent ethics committee at each site and conducted 
in accordance with the International Conference on Har-
monisation Guideline for Good Clinical Practice and the 
ethical principles of the Declaration of Helsinki. Detailed 
study methodology has been published previously [11]. Each 
patient provided written informed consent to participate in 
the study.
Adults with a confirmed diagnosis of CS and 24-h mUFC 
levels ≥ 1.5 × upper limit of normal (ULN) were enrolled in a 
dose-titration phase (to establish a therapeutic dose) that was 
followed by a 6-month maintenance phase and a 6-month 
extended evaluation phase (Fig. 1). During the dose-titration 
phase, the levoketoconazole dose was adjusted (within the 
range of 150 mg to 600 mg twice daily) based on mUFC 
response and tolerability. The levoketoconazole dose was 
considered therapeutic if (a) mUFC was normalized (i.e., 
≤ULN) or (b) a levoketoconazole dose of 600 mg twice 
daily or a maximal tolerated dose was reached and there 
was a clinically meaningful partial response in the opinion 
of the investigator. Patients for whom a therapeutic dose 
was identified were eligible to enter the maintenance phase. 
Investigators were instructed not to increase the dose of 
Dose titration
2–21 weeks
Titrate in 150-mg increments up 
to a maximum 600 mg 2x dailya until 
mUFC normalization is achievedb
Maintenance
6 months
Maintain UFC normalization after 
6 months without a dose increase 
Extended evaluation
6 months
Exploration of long-term safety 
and maintenance of benefit
D1 M1 M2 M3
Assessments
M4 M5 M6
Primary endpoint 
Normalization of mUFC at 
EoM without a dose increase 
during the maintenance phase
Fig. 1  Study design. D day, EoM  end of maintenance, M month, 
mUFC mean urinary free cortisol, UFC urinary free cortisol, ULN 
upper limit of normal. aAll patients started at the protocol-mandated 
dose of 150 mg twice daily, but a reduction to 150 mg once daily to 
improve tolerability was allowed. bA therapeutic dose was consid-
ered established when 1) mUFC was normalized (i.e., ≤  ULN) or 
2) levoketoconazole dose of 600 mg twice daily or a maximal toler-
ated dose was reached and there was a clinically meaningful partial 
response in the opinion of the investigator
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levoketoconazole during the maintenance phase unless it 
was necessary to maintain cortisol control or in response to 
safety or tolerability issues. 
Outcomes
The primary endpoint was the percentage of patients who 
demonstrated mUFC normalization (mUFC ≤ ULN) at the 
end of the 6-month maintenance phase with no dose increase 
during maintenance, as previously described [11].
Secondary endpoints included change from baseline to 
maintenance phase in investigator-assessed clinical signs 
and symptoms and patient-reported QoL and depression. 
Clinical signs and symptoms of CS—moon facies, facial 
plethora, striae, bruising, supraclavicular fat, irregular 
menstruation (females only), dysmenorrhea (females only), 
acne, hirsutism (females only), and peripheral edema—were 
assessed at baseline, at the start of the maintenance phase, 
and monthly during maintenance therapy. The first 7 items 
(Cushingoid physical appearance and menstrual status, as 
listed above) were rated by individual investigators on a 
scale from 0 to 3, for which 0 = absent, 1 = mild, 2 = moder-
ate, and 3 = severe (total score range, 0–21). As only 5 of 
these 7 signs and symptoms apply to males, the total score 
from males was multiplied by 7 and divided by 5 in order 
to standardize the score for both sexes. Acne was graded 
by investigators according to Doshi et al. [13]. Hirsutism 
was evaluated in females according to the rating system 
described by Hatch et al. [14], as originally described by 
Ferriman and Gallwey [15]. Peripheral edema was evalu-
ated in 3 locations (lower calf above the medial malleolus, 
behind the medial malleolus, and dorsum of the foot) and 
rated according to Brodovicz et al. [16], which was origi-
nally described by Seidel et al. [17]. The acne global score 
ranged from 0 to 44, for which 0 indicated none, 1–18 was 
mild, 19–30 was moderate, 31–38 was severe, and ≥ 39 was 
very severe. The hirsutism total score ranged from 0 (none) 
to 36 (worst). The peripheral edema total score ranged from 
0 (none) to 12 (worst).
Quality of life was measured using the CushingQoL ques-
tionnaire, a validated 12-item patient-reported measure spe-
cific to CS [18]. Patients self-rated each item on a 5-point 
scale from 1 (“always” or “very much”) to 5 (“never” or “not 
at all”), and the total score was standardized on a scale from 
0 (worst QoL) to 100 (best QoL). Severity of depression 
was evaluated using the Beck Depression Inventory II (BDI-
II), a validated 21-item patient-reported questionnaire [19]. 
Patients self-rated each item on a scale from 0 to 3 based on 
how they were feeling during the previous 2 weeks, yielding 
a total score that ranged from 0 (best) to 63 (worst). BDI-II 
scores from 0 to 13 indicated no or minimal depression, 
14–19 indicated mild depression, 20–28 indicated moderate 
depression, and 29–63 indicated severe depression [20]. The 
CushingQoL questionnaire and BDI-II were administered at 
baseline and Months 3 and 6 of the maintenance phase. The 
BDI-II was added as an outcome measure after the study was 
initiated and was administered only to patients who enrolled 
after the protocol was amended.
Serum testosterone was measured in a central laboratory 
as total, free, and bioavailable testosterone. Total testoster-
one was measured using liquid chromatography–tandem 
mass spectrometry. Free testosterone and bioavailable tes-
tosterone (free testosterone + albumin-bound testosterone) 
were derived from total testosterone and serum albumin and 
sex hormone binding globulin levels (measured using immu-
noassay) by the Södergård method [21]. Testosterone levels 
were analyzed separately for males and females.
Statistical analysis
The primary endpoint (mUFC normalization without a 
dose increase during maintenance phase) analysis has been 
described previously [11]. For the secondary outcomes 
presented in this paper, analyses included all patients who 
entered the maintenance phase of the study (the maintenance 
population). Scores at baseline of the dose-titration phase; 
Day 1 of the maintenance phase; and after Months 1, 2, 3, 
4, 5, and 6 of maintenance (for clinical signs and symptoms 
and testosterone levels) or Months 3 and 6 of maintenance 
(for CushingQoL and BDI-II scores) were summarized using 
descriptive statistics. Mean changes from baseline to each 
timepoint were analyzed for statistical significance using 
paired t-tests; no adjustments were made for multiplicity. 
Post hoc multiple regression analyses evaluated the effect of 
mUFC value at Month 6 and change from baseline to Month 
6 in mUFC level on change from baseline to Month 6 in each 
of the acne, hirsutism, peripheral edema, CushingQoL, and 
BDI-II scores separately, adjusting for the respective base-
line scores and baseline mUFC. Post hoc multiple regression 
analyses evaluated the effect of mUFC value at Month 6 
on change from baseline to Month 6 in testosterone levels 
in males and females, separately, adjusting for the baseline 
levels of testosterone and mUFC.
Exploratory analyses investigated categorical shifts 
from baseline to Month 6 in measures of CS signs and 
symptoms, QoL, and depression. For the 7-item scale of 
Cushingoid physical appearance and menstruation status, 
the percentage of patients with a categorical shift in severity 
from baseline to Month 6 (or the last visit in the mainte-
nance phase) was calculated for improvement (in patients 
with the sign/symptom at baseline [i.e., baseline score ≠ 
0]), worsening (in patients with the sign/symptom absent 
or less than severe at baseline [i.e., baseline score < 3]), 
and no change. On the CushingQoL questionnaire, a score 
increase of ≥ 10.1 has been identified as a threshold for clini-
cally meaningful improvement, referred to as a minimally 
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important difference (MID) [22, 23]. For patients with data 
at baseline and the corresponding study visit, the percent-
ages of patients who met or exceeded the MID threshold 
were calculated at Months 3 and 6. For the BDI-II score, 
the percentages of patients with categorical shifts in severity 
from baseline (minimal, mild, moderate, and severe) were 
also calculated at Months 3 and 6.
Results
Patients
A total of 94 patients enrolled in the study and received ≥ 1 
dose of levoketoconazole (intent-to-treat population); 77 
patients entered the maintenance phase (maintenance popu-
lation), and 61 (79%) completed maintenance. The extended 
evaluation findings are not included in the current analyses, 
as they were derived from quarterly visits and were consid-
ered exploratory rather than secondary outcomes. Baseline 
characteristics of the maintenance population are shown 
in Table 1, and baseline scores in Table 2. Mean baseline 
scores for clinical signs and symptoms were generally con-
sistent with mild symptom severity. However, the mean 
CushingQoL total score at baseline was 44.3 (median 45.8), 
ranging up to 94; this was indicative of a population with 
moderate impairment of health-related QoL and suggested 
that the patient-reported QoL score captured impairment not 
reflected by investigator assessments of clinical signs and 
symptoms. The mean baseline score of 17.1 on the BDI-II 
was indicative of mild depression [20]. The total daily dose 
of levoketoconazole at the start of the maintenance phase 
was 300 mg in 31.2% of patients, 450 mg to 750 mg in 
42.9%, and 900 mg to 1200 mg in 26.0%.
Clinical signs and symptoms of Cushing’s syndrome
Significant mean improvements from baseline to Month 
6 were observed in the acne global score, hirsutism total 
score (females only), and peripheral edema total score. Mean 
improvement was statistically significant beginning on Day 
1 of maintenance (i.e., after the end of dose-titration) for 
hirsutism (females only; mean change − 1.9; P < 0.0001), by 
the end of Month 1 of maintenance for acne (mean change 
− 1.2; P = 0.0481), and by Month 4 of maintenance for 
peripheral edema (mean change − 0.5; P = 0.0052; Fig. 2). 
Mean changes from baseline to Month 6 were − 1.8 for acne 
global score (P = 0.0063), − 2.6 for hirsutism total score 
(females only; P = 0.0008), and − 0.4 for peripheral edema 
total score (P = 0.0295). No significant linear relationships 
between mUFC value or change from baseline at Month 6 
and changes from baseline in acne, hirsutism, or peripheral 
edema scores at Month 6 were observed. 
Table 1  Demographic and baseline characteristics (maintenance pop-
ulation)
BMI body mass index, CS Cushing’s syndrome, mUFC mean urinary 
free cortisol, SD standard deviation, UFC urinary free cortisol, ULN 
upper limit of normal
a n = 75; 2 patients did not have ≥ 2 adequate urine samples at base-
line
b ULN for UFC = 138 nmol/24 h (50 µg/24 h)
c One patient with mUFC < 1.5× ULN was excluded because of inad-
equate urine collection
Characteristic Patients (N = 77)
Age, years, mean (SD) 44.1 (12.9)
Female, n (%) 61 (79.2)
Race, n (%)
 White 73 (94.8)
 Black 1 (1.3)
 Other/unknown 3 (3.9)
BMI, kg/m2, mean (SD) 29.9 (7.1)
Time since CS diagnosis, months
 Mean (SD) 65.1 (69.9)
 Median (range) 37.5 (0.7–245.4)
 Diagnosis of Cushing’s disease, n (%) 67 (87.0)
 Treatment-naive for CS, n (%) 23 (29.9)
mUFCa (nmol/24 h)
 Mean (SD) 602.3 (560.4)
 Median (range) 410.5 (162.0–3229.5)
mUFCa (mcg/24 h)
 Mean (SD) 218.2 (203.0)
 Median (range) 148.7 (58.7–1170.1)
mUFCa (×  ULNb)
 Mean (SD) 4.4 (4.1)
 Median (range) 3.0 (1.2–23.4)c
Table 2  Baseline scores on selected secondary outcome measures 
(maintenance population)
BDI-II Beck Depression Inventory II, CSS clinical signs and symp-
toms, QoL quality of life, SD standard deviation
a Moon facies, facial plethora, striae, bruising, supraclavicular fat, 
irregular menstruation (females only), dysmenorrhea (females only). 
As only 5 of these 7 signs and symptoms apply to males, their total 
score was multiplied by 7 and divided by 5 in order to standardize the 
score for both sexes
Outcome Measure Patients (N = 77)
n Mean (SD) Median (range)
Clinical signs and symptoms
 Acne, global score 75 2.8 (5.8) 0.0 (0–25)
 Hirsutism (females), total score 60 7.8 (5.7) 7.0 (0–24)
 Peripheral edema, total score 75 1.0 (1.8) 0.0 (0–9)
 7 other CSS, total  scorea 61 4.3 (3.8) 3.0 (0–13)
CushingQoL, total score 74 44.3 (21.3) 45.8 (6–94)
BDI-II, total score 59 17.1 (12.9) 14.0 (0–52)
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The mean change from baseline of −  0.8 for the 
total score of 7 items that evaluated Cushingoid physi-
cal appearance and menstrual status (moon facies, facial 
plethora, striae, bruising, supraclavicular fat, irregular 
menstruation [females only], and dysmenorrhea [females 
only]) was not statistically significant (P = 0.1085). For 
individual clinical signs and symptoms, improvement from 
baseline for patients with baseline score ≠ 0 (as deter-
mined by categorical shift in item score [0 = “absent” 
and 3 = “severe”]) was observed in ≥ 38.1% of patients, 
whereas symptom worsening for those with baseline 
score < 3 was relatively less common (≤ 13.1% of patients) 
(Fig. 3). 
Quality of life and depression
Mean total score on the CushingQoL questionnaire increased 
(improved) from 44.3 at baseline to 50.9 at Month 3 and 
53.9 at Month 6 (Fig. 4). Mean changes from baseline in 
total score were significant at Month 3 (6.9; P = 0.0018) and 
Month 6 (10.6; P < 0.0001) assessments. The MID threshold 
of 10.1 points was met (or exceeded) by 40.0% of individual 
patients at Month 3 and 47.1% at Month 6 (among the 60 
and 51 patients with available data for Month 3 and Month 
6, respectively). 
Mean scores on the BDI-II generally declined 
(improved) during treatment, from 17.1 at baseline to 14.4 
and 12.5 at Months 3 and 6, respectively (Fig. 5a). The 
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Baseline
(n=61)
Day 1
(n=61)
Month 3
(n=55)
Month 4
(n=54)
Month 5
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Month 1
(n=60)
Month 2
(n=58)
Month 6
(n=48)
–0.4
–0.4
–0.6
–0.7 –0.7
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Fig. 2  Mean scores for clinical signs and symptoms of Cushing’s 
syndrome from baseline through the end of the maintenance phase 
for a acne global score, b hirsutism total score (females), c peripheral 
edema total score, and d total score for 7 other signs and symptoms 
(maintenance population). Two-sided P value from the paired t-test 
that was performed on the mean change from baseline to each time-
point. Acne global score could range from 0 to 44, where 0 = none, 
1–18 = mild, 19–30 = moderate, 31–38 = severe, and ≥39 = very 
severe. Hirsutism total score could range from 0 (none) to 36 (worst). 
Peripheral edema total score could range from 0 (none) to 12 (worst). 
Seven other signs or symptoms (moon facies, facial plethora, striae, 
bruising, supraclavicular fat, irregular menstruation [females only], 
dysmenorrhea [females only]) were rated by investigators on a scale 
from 0 to 3, for which 0 = absent, 1 = mild, 2 = moderate, and 3 = 
severe (total score range, 0–21). As only 5 of these 7 signs and symp-
toms apply to males, their total score was multiplied by 7 and divided 
by 5 in order to standardize the score for both sexes. SEM  standard 
error of the mean. *P < 0.05; †P < 0.01; ‡P < 0.001
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mean change from baseline was statistically significant 
at Month 6 (– 4.3; P = 0.0043). In patients with baseline 
depression severity that was mild, moderate, or severe, 
categorical shifts in severity reflected improvement in the 
majority of patients at Month 3 and Month 6 (Fig. 5b).
No significant relationship was found between mUFC 
value or change from baseline at Month 6 and changes 
from baseline in CushingQoL or BDI-II scores at Month 
6.
Testosterone levels
In males, mean total, bioavailable, and free testosterone 
increased non-significantly from baseline to Month 6 (Fig. 6; 
Table 3). In females, reductions in mean total, bioavailable, 
and free testosterone were observed beginning at Day 1 
of the maintenance phase and continued through Month 6 
(P < 0.0001). There were no significant linear relationships 
between change in total, bioavailable, and free testosterone 
levels in males and females and mUFC value at Month 6.
Discussion
SONICS, a large, multinational, phase 3 trial, demonstrated 
that treatment with levoketoconazole normalized mUFC 
after 6 months of maintenance therapy, along with improv-
ing investigator-graded CS signs and symptoms, patient-
reported QoL and depression symptoms, and testosterone 
levels [11]. In this report, the effects of levoketoconazole 
on clinical signs and symptoms, patient-reported outcomes, 
and associated biochemical markers were further evaluated.
The investigator-graded signs and symptoms of CS—
acne, hirsutism (in females), and peripheral edema—sig-
nificantly and consistently improved during 6 months of 
open-label levoketoconazole maintenance therapy. Improve-
ments in acne and hirsutism were observed early in the 
maintenance phase, following 2–21 weeks of individualized 
treatment in the dose-titration phase. Patient-reported QoL 
significantly improved, and symptoms of depression signifi-
cantly decreased during treatment with levoketoconazole.
Significant mean reductions in testosterone levels were 
noted in females, likely accounting for the investigator-
assessed improvements noted in acne and hirsutism. 
Fig. 3  Improvement, no change, 
or worsening in clinical signs 
and symptoms of Cushing’s 
syndrome, based on categorical 
shift in item score (maintenance 
population). Improvement was 
assessed in patients with signs 
or symptoms at baseline (base-
line score ≠ 0) and worsening 
was assessed in patients with 
absent or less than severe signs 
or symptoms at baseline (base-
line score < 3). For each item, 
investigator rating scale was 0 = 
absent, 1 = mild, 2 = moderate, 
and 3 = severe
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Fig. 4  Mean scores from baseline through the end of the maintenance 
phase for CushingQoL total score (maintenance population). Two-
sided P value from the paired t-test that was performed on the mean 
change from baseline to each timepoint. CushingQoL score could 
range from 0 (worst) to 100 (best). QoL quality of life, SEM stand-
ard error of the mean. *P < 0.01 versus baseline; †P < 0.001 versus 
baseline
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Interestingly, testosterone did not decline in males, but 
rather trended toward an increase on average. The reduc-
tion of testosterone in females also has been seen with keto-
conazole treatment in patients with CS [24–26]. Females 
with active CS typically experience hyperandrogenism as a 
result of stimulated adrenal androgen production, which can 
be suppressed by ketoconazole, an inhibitor of CYP17A1, 
and other enzymes in the androgen synthesis pathway [10, 
27]. On the other hand, males with active CS tend to experi-
ence reduced testosterone production due to glucocorticoid-
induced gonadotropin suppression and subsequent reduction 
in testicular testosterone production [27, 28]. As ketocona-
zole tends to suppress testosterone production in males with 
a normal hypothalamus-pituitary-gonadal axis [29, 30], 
one might expect that it would also suppress testosterone in 
CS. However, case studies suggest that ketoconazole may 
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improve or not change serum testosterone in males with CS 
[31, 32], perhaps via improvement of gonadotropin secre-
tion that, in turn, stimulates testicular testosterone synthesis. 
The current study suggests that levoketoconazole is similar 
to ketoconazole in this regard, without any negative (and, 
possibly, with positive) effects on gonadal function in men.
In contrast to the significant improvements in acne, hir-
sutism, and peripheral edema scores, a 7-item composite 
score of Cushingoid appearance and menstruation status 
that included moon facies, facial plethora, striae, bruis-
ing, supraclavicular fat, and irregular menstruation and 
dysmenorrhea, which indicated only mild abnormality at 
baseline, decreased, but not significantly, during treatment. 
To be nominally significant (at P < 0.05) at Month 6, a mean 
decrease in the total score of − 0.94, representing a rela-
tive reduction in the mean score of 22%, would have been 
required, whereas a reduction of − 0.8 was observed. As a 
minimal clinically important difference in this score has not 
been established, it is unknown whether the reduction from 
baseline in the mean score noted in the present study is of 
potential clinical relevance. The fact that photographs were 
not taken at every visit may have limited the investigators’ 
Fig. 6  Mean free testosterone 
levels from baseline through the 
end of the maintenance phase in 
a males and b females (mainte-
nance population). Two-sided 
P value from the paired t-test 
that was performed on the mean 
change from baseline to each 
timepoint. Free testosterone ref-
erence levels: males aged 18–69 
years, 4.6–22.4 ng/dL (0.160–
0.777 nmol/L); males aged 
70–89 years, 0.6–7.3 ng/dL 
(0.021–0.253 nmol/L); females 
aged 18–69 years, 0.02–0.5 ng/
dL (0.0007–0.017 nmol/L); 
females aged 70–89 years, 
0.03–0.5 ng/dL (0.001–0.017 
nmol/L). SEM standard error of 
the mean. *P < 0.0001
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ability to identify changes in patients’ physical appearance 
over time.
Patient-reported symptoms of depression, which were 
mild at baseline, nonetheless improved with therapy, and 
QoL, which was moderately impaired at baseline, sub-
stantially improved. Notably, the improvements in patient-
reported and physician-assessed outcomes were observed 
in the context of substantial mean reductions in mUFC lev-
els. In 55 maintenance phase completers with UFC data, 
mUFC normalized at Month 6 in 34 patients (62%), and 
43 patients (78%) experienced a decrease of at least 50% 
(or normalization) in mUFC [11]. However, no linear cor-
relation was found between improvement in clinical signs 
and symptoms (acne, hirsutism, peripheral edema), Cush-
ingQoL, or BDI-II scores and changes in or absolute values 
of mUFC from baseline to Month 6. This finding is similar 
to a prior prospective multinational study of pasireotide in 
Cushing’s disease that demonstrated a lack of correlation 
between baseline UFC levels and baseline severity of a large 
number of features of clinical hypercortisolism [33]. It may 
be the case that the severity of CS clinical features is more 
strongly associated with the duration of hypercortisolism 
than the UFC per se. Consistent with this hypothesis, a sig-
nificant correlation was reported between change in Cush-
ingQoL score and change in mUFC levels after 12 months, 
but not after 6 months, of treatment with pasireotide [22]. 
Therefore, although the average duration of therapy at the 
end of Month 6 of the maintenance phase in the SONICS 
study was approximately 230 days [11], it may not have been 
sufficiently long to observe a correlation between improve-
ment in clinical features of CS and mUFC levels.
The CushingQoL questionnaire includes items specific 
to the disease (e.g., “I’m worried about the changes in my 
physical appearance”), as well as more general health-related 
QoL items (e.g., “My illness affects my everyday activities”) 
[18]. The mean baseline score, which indicated moderate 
QoL impairment, appears to indicate that the impact of the 
disease on patient perceptions of illness is not captured by 
the investigator assessments of signs and symptoms, at least 
with the instruments used in this study. This issue deserves 
further research, as a recently published study of acromeg-
aly, another rare pituitary disease, suggests that there is poor 
concordance between physician and patient perceptions of 
disease and treatment impact on the frequency and severity 
of symptoms [34]. Nevertheless, whether similar discord-
ance exists in the medically treated CS population remains 
unknown.
Depressive symptoms were not severe at baseline, as indi-
cated by the mean BDI-II score; yet, a statistically significant 
mean decrease was observed at Month 6 of the maintenance 
phase. Similar baseline impairment and degree of improve-
ment in BDI-II score with medical therapies for CS were 
noted in prospective studies of mifepristone [35] and pasire-
otide [36], but to our knowledge this is the first published 
prospective phase 3 study of an adrenal steroidogenesis 
inhibitor that assessed this particular outcome [11].
In SONICS, the most commonly reported adverse events 
during the dose-titration and maintenance phases were nau-
sea (32% of patients) and headache (28% of patients) [11]. 
QT interval prolongation, identified as an adverse event in 
5 patients (5%), was reversible with temporary drug dis-
continuation. Reversible elevations > 3 × ULN of alanine 
aminotransferase were observed at least once during the 
maintenance phase in 11% of patients. In a separate analy-
sis of metabolic parameters from SONICS data, significant 
mean improvement from baseline to Month 6 was observed 
in biomarkers of cardiovascular risk, both in the overall 
patient population [11] and in patients with comorbid type 
2 diabetes [37].
The longitudinal design and the large number of 
patients in SONICS are study strengths that allow evalu-
ation of improvements over the course of treatment with 
levoketoconazole. The main limitations of the study 
are the use of open-label treatment (both participants 
and investigators aware), the lack of a placebo arm, and 
Table 3  Testosterone levels from baseline through month 6 (mainte-
nance population)
SD standard deviation
a n = 16 for males and n = 58 for females
b n = 9 for males and n = 45 for females
c Two-sided P value from the paired t-test that was performed on the 
mean change from baseline to Month 6
Baselinea Month  6b P  valuec
Males
 Total testosterone 0.1184
  Mean (SD), nmol/L 10.90 (7.91) 22.44 (19.24)
  Mean (SD), ng/dL 314.0 (228.0) 646.7 (554.4)
 Bioavailable testosterone 0.3709
  Mean (SD), nmol/L 3.82 (4.07) 4.36 (4.05)
  Mean (SD), ng/dL 110.1 (117.3) 125.5 (116.8)
 Free testosterone 0.3834
  Mean (SD), nmol/L 0.18 (0.16) 0.20 (0.17)
  Mean (SD), ng/dL 5.1 (4.7) 5.8 (4.9)
Females
 Total testosterone < 0.0001
  Mean (SD), nmol/L 0.873 (0.533) 0.518 (0.354)
  Mean (SD), ng/dL 25.2 (15.4) 14.9 (10.2)
 Bioavailable testosterone < 0.0001
  Mean (SD), nmol/L 0.233 (0.192) 0.099 (0.095)
  Mean (SD), ng/dL 6.7 (5.5) 2.9 (2.7)
 Free testosterone < 0.0001
  Mean (SD), nmol/L 0.011 (0.011) 0.004 (0.006)
  Mean (SD), ng/dL 0.32 (0.31) 0.12 (0.16)
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unblinded study assessments. Knowledge of study treat-
ment and assessments made by unblinded assessors are 
potentially important sources of bias, particularly with 
regard to subjective assessments, such as patient-reported 
QoL and depression symptom inventory score. In addition, 
because of the disproportionate representation of etiolo-
gies of CS among patients in this study (67 patients with 
Cushing’s disease and 6 patients with adrenal-dependent 
CS in the maintenance population), a correlation analysis 
between changes in signs and symptoms and the type of 
CS was unlikely to provide meaningful information and 
therefore was not undertaken.
In conclusion, levoketoconazole provides sustained 
improvements in relevant investigator-assessed signs 
and symptoms and patient-reported QoL and depression 
outcomes for patients with CS; these improvements are 
associated with changes in biochemical disease markers 
including serum testosterone and mUFC levels.
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